Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

Exclusion Criteria

• •Any indication for oral anticoagulant or dual antiplatelet treatment
• •Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers within 14 days and during study treatment and during:
• •Increased bleeding risk including:
• •Diabetic patients with HbAlC \> 10% at screening
• •Contraindication to clopidogrel, ASA, or ticagrelor - A history of alcohol and/or substance abuse that could interfere with conduct of the trial
• •Patients requiring dialysis
• •Patients scheduled for revascularization (e.g., PCI, CABG) during the study period
• •Any acute or chronic unstable condition in the past 30 days
• •Known active or recurrent hepatic disorder
• •Patients who had ACS or stent placed within 12 months of screening
• •History of Uric Acid nephropathy